clinical trial · NCT04261712
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
AcromegalyPaltusotine
brief summary
A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.
started
Jan 29, 2020
primary completion
Mar 1, 2028
completion
Mar 1, 2028
last updated
Apr 22, 2026
official title
An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol